Stock Analiz

Alaunos Therapeutics, Inc. TCRT

Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026

$1.63Market cap $7M
Open the interactive analysis →

Alaunos Therapeutics, Inc. (TCRT) is a healthcare company listed in the US with a market value of about $7M. In the twelve months to June 30, 2026 it had revenue of $3000 and net income of -$4M, a net margin of -133666.7%.

Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).

Key numbers: a 5-year average ROIC of -177%.

About Alaunos Therapeutics

Alaunos Therapeutics is listed in the US and classified in biotechnology: pharmaceutical preparations. Revenue went from $7M in 2016 to $5000 in 2025, a decline of about 55.2% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 35% over three years (dilution for shareholders). It spends 27260% of revenue on research and development.

Score: 1.0 / 5

Value0/5
Future growth1/5
Track record0/5
Financial health4/5
Shareholder returns0/5

Checks passed

  • Strong R&D investment or growth above 20%
  • More cash than debt, or low debt to equity
  • Interest covered more than 5 times
  • Debt below 3 years of free cash flow
  • Liabilities below 60% of assets

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S2,243.0
P/B10.3
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield-44.1%
Shareholder yield0.0%
Intrinsic value vs. price—

Growth and quality

Revenue growth (1 yr)-50.0%
Revenue growth (5 yrs, per year)—
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-48993.6%
ROIC (5-yr avg.)-177.3%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$3000$5000$10000$5000$3M$398000$0—$146000$16M$7M
Net income-$4M-$4M-$5M-$5M-$38M-$79M-$80M-$118M-$53M-$54M-$165M
Free cash flow—-$3M-$5M-$30M-$29M-$65M-$67M-$41M-$50M-$55M-$59M
EPS (diluted)$-1.91$-2.20$-2.92$-21.97$-26.10$-55.50$-57.00$-105.00$144.00$-79.50$-198.00
Net margin-133666.7%-83520.0%-46790.0%-93580.0%-1291.2%-19786.7%——-36381.5%-341.7%-2409.2%
ROIC—-155.0%-184.3%-429.2%-47.8%-70.1%-49.3%-46.9%-49.8%——

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Does Alaunos Therapeutics pay a dividend?

Not currently.

Is Alaunos Therapeutics a good stock to buy?

We do not give buy or sell advice. Alaunos Therapeutics scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.